Drug General Information (ID: DDIDL7AI09)
Drug Name			Saquinavir		Drug Info		Amisulpride		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anti-Hiv Agents				Antipsychotic Agents
Structure

Mechanism of Saquinavir-Amisulpride Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Saquinavir				Amisulpride
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Saquinavir and Amisulpride

Recommended Action
Management		Coadministration of ritonavir-boosted saquinavir with other drugs that can prolong the QT interval is considered contraindicated.

References
1	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
2	Biondi L "Health Canada endorsed important safety information on Invirase (saquinavir mesylate)." .
3	Canadian Pharmacists Association.
4	Cerner Multum, Inc. "Australian Product Information.".
5	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6	Product Information. Invirase (saquinavir). Roche Laboratories, Nutley, NJ.
7	FDA. U.S. Food and Drug Administration "FDA drug safety communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms.".